<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37788227</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1553-7374</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>PLoS pathogens</Title><ISOAbbreviation>PLoS Pathog</ISOAbbreviation></Journal><ArticleTitle>VP2 residue N142 of coxsackievirus A10 is critical for the interaction with KREMEN1 receptor and neutralizing antibodies and the pathogenicity in mice.</ArticleTitle><Pagination><StartPage>e1011662</StartPage><MedlinePgn>e1011662</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1011662</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.ppat.1011662</ELocationID><Abstract><AbstractText>Coxsackievirus A10 (CVA10) has recently emerged as one of the major causative agents of hand, foot, and mouth disease. CVA10 may also cause a variety of complications. No approved vaccine or drug is currently available for CVA10. The residues of CVA10 critical for viral attachment, infectivity and in vivo pathogenicity have not been identified by experiment. Here, we report the identification of CVA10 residues important for binding to cellular receptor KREMEN1. We identified VP2 N142 as a key receptor-binding residue by screening of CVA10 mutants resistant to neutralization by soluble KREMEN1 protein. The receptor-binding residue N142 is exposed on the canyon rim but highly conserved in all naturally occurring CVA10 strains, which provides a counterexample to the canyon hypothesis. Residue N142 when mutated drastically reduced receptor-binding activity, resulting in decreased viral attachment and infection in cell culture. More importantly, residue N142 when mutated reduced viral replication in limb muscle and spinal cord of infected mice, leading to lower mortality and less severe clinical symptoms. Additionally, residue N142 when mutated could decrease viral binding affinity to anti-CVA10 polyclonal antibodies and a neutralizing monoclonal antibody and render CVA10 resistant to neutralization by the anti-CVA10 antibodies. Overall, our study highlights the essential role of VP2 residue N142 of CVA10 in the interactions with KREMEN1 receptor and neutralizing antibodies and viral virulence in mice, facilitating the understanding of the molecular mechanisms of CVA10 infection and immunity. Our study also provides important information for rational development of antibody-based treatment and vaccines against CVA10 infection.</AbstractText><CopyrightInformation>Copyright: © 2023 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zeyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Xingyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institutional Center for Shared Technologies and Facilities of Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Kexin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institutional Center for Shared Technologies and Facilities of Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Jiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institutional Center for Shared Technologies and Facilities of Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hao</LastName><ForeName>Pei</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chao</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-8658-9009</Identifier><AffiliationInfo><Affiliation>Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Pathog</MedlineTA><NlmUniqueID>101238921</NlmUniqueID><ISSNLinking>1553-7366</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C486077">Kremen protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="Y">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="Y">Viral Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014774" MajorTopicYN="N">Virulence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="Y">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>3</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>3</Day><Hour>13</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37788227</ArticleId><ArticleId IdType="pmc">PMC10547193</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1011662</ArticleId><ArticleId IdType="pii">PPATHOGENS-D-23-00929</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bian L, Gao F, Mao Q, Sun S, Wu X, Liu S, et al.. Hand, foot, and mouth disease associated with coxsackievirus A10: more serious than it seems. Expert Rev Anti Infect Ther. 2019;17(4):233–42. Epub 2019/02/23. doi: 10.1080/14787210.2019.1585242 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2019.1585242</ArticleId><ArticleId IdType="pubmed">30793637</ArticleId></ArticleIdList></Reference><Reference><Citation>Banno F, Shibata S, Hasegawa M, Matsuoka S, Okumura A. Acute flaccid myelitis presumably caused by coxsackie virus A10. Pediatr Int. 2021;63(1):104–5. Epub 2021/01/16. doi: 10.1111/ped.14361 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ped.14361</ArticleId><ArticleId IdType="pubmed">33448537</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu QB, Zhang XA, Wo Y, Xu HM, Li XJ, Wang XJ, et al.. Circulation of Coxsackievirus A10 and A6 in hand-foot-mouth disease in China, 2009–2011. PLoS One. 2012;7(12):e52073. Epub 2012/12/29. doi: 10.1371/journal.pone.0052073 ; PubMed Central PMCID: PMC3525556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052073</ArticleId><ArticleId IdType="pmc">PMC3525556</ArticleId><ArticleId IdType="pubmed">23272213</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuschino ME, Lamson DM, Rush K, Carbone LS, Taff ML, Hua Z, et al.. Detection of coxsackievirus A10 in multiple tissues of a fatal infant sepsis case. J Clin Virol. 2012;53(3):259–61. Epub 2012/01/03. doi: 10.1016/j.jcv.2011.12.011 S1386-6532(11)00518-X [pii]. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2011.12.011</ArticleId><ArticleId IdType="pubmed">22209288</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji T, Guo Y, Huang W, Shi Y, Xu Y, Tong W, et al.. The emerging sub-genotype C2 of CoxsackievirusA10 Associated with Hand, Foot and Mouth Disease extensively circulating in mainland of China. Sci Rep. 2018;8(1):13357. Epub 2018/09/08. doi: 10.1038/s41598-018-31616-x [pii]. ; PubMed Central PMCID: PMC6127217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-31616-x</ArticleId><ArticleId IdType="pmc">PMC6127217</ArticleId><ArticleId IdType="pubmed">30190558</ArticleId></ArticleIdList></Reference><Reference><Citation>Munivenkatappa A, Yadav PD, Nyayanit DA, Majumdar TD, Sangal L, Jain S, et al.. Molecular diversity of Coxsackievirus A10 circulating in the southern and northern region of India [2009–17]. Infect Genet Evol. 2018;66:101–10. Epub 2018/09/16. doi: 10.1016/j.meegid.2018.09.004 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2018.09.004</ArticleId><ArticleId IdType="pubmed">30217658</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, He S, Yan Q, Xu X, Wu W, Ge S, et al.. Severe hand, foot and mouth disease associated with Coxsackievirus A10 infections in Xiamen, China in 2015. J Clin Virol. 2017;93:20–4. Epub 2017/06/04. doi: 10.1016/j.jcv.2017.05.011 [pii] .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2017.05.011</ArticleId><ArticleId IdType="pubmed">28577423</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q, Ding J, Cao J, Huang Q, Hong C, Yang B. Epidemiological and etiological characteristics of hand, foot, and mouth disease in Wuhan, China from 2012 to 2013: outbreaks of coxsackieviruses A10. J Med Virol. 2015;87(6):954–60. Epub 2015/03/11. doi: 10.1002/jmv.24151 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24151</ArticleId><ArticleId IdType="pubmed">25754274</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Liu H, Cao Z, Xu J, Guo J, Zhao L, et al.. Epidemiology of Hand, Foot, and Mouth Disease and Genetic Evolutionary Characteristics of Coxsackievirus A10 in Taiyuan City, Shanxi Province from 2016 to 2020. Viruses. 2023;15(3). Epub 2023/03/31. doi: 10.3390/v15030694 ; PubMed Central PMCID: PMC10052898.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15030694</ArticleId><ArticleId IdType="pmc">PMC10052898</ArticleId><ArticleId IdType="pubmed">36992403</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan X, Zhang C, Wang X, Ren X, Peng H, Tang X, et al.. Molecular epidemiology and clinical features of hand, foot and mouth disease requiring hospitalization after the use of enterovirus A71 inactivated vaccine in chengdu, China, 2017–2022: a descriptive study. Emerg Microbes Infect. 2022;11(1):2510–9. Epub 2022/09/15. doi: 10.1080/22221751.2022.2125346 ; PubMed Central PMCID: PMC9621254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2125346</ArticleId><ArticleId IdType="pmc">PMC9621254</ArticleId><ArticleId IdType="pubmed">36103331</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng XD, Tong Y, Wei ZN, Wang L, Mai JY, Wu Y, et al.. Epidemical and etiological study on hand, foot and mouth disease following EV-A71 vaccination in Xiangyang, China. Sci Rep. 2020;10(1):20909. Epub 2020/12/03. doi: 10.1038/s41598-020-77768-7 ; PubMed Central PMCID: PMC7708472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-77768-7</ArticleId><ArticleId IdType="pmc">PMC7708472</ArticleId><ArticleId IdType="pubmed">33262488</ArticleId></ArticleIdList></Reference><Reference><Citation>Nhan LNT, Khanh TH, Hong NTT, Van HMT, Nhu LNT, Ny NTH, et al.. Clinical, etiological and epidemiological investigations of hand, foot and mouth disease in southern Vietnam during 2015–2018. PLoS Negl Trop Dis. 2020;14(8):e0008544. Epub 2020/08/18. doi: 10.1371/journal.pntd.0008544 ; PubMed Central PMCID: PMC7451980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0008544</ArticleId><ArticleId IdType="pmc">PMC7451980</ArticleId><ArticleId IdType="pubmed">32804980</ArticleId></ArticleIdList></Reference><Reference><Citation>Lizasoain A, Mir D, Martinez N, Colina R. Coxsackievirus A10 causing hand-foot-and-mouth disease in Uruguay. Int J Infect Dis. 2020;94:1–3. Epub 2020/02/23. doi: 10.1016/j.ijid.2020.02.012 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.02.012</ArticleId><ArticleId IdType="pubmed">32081777</ArticleId></ArticleIdList></Reference><Reference><Citation>Upala P, Apidechkul T, Suttana W, Kullawong N, Tamornpark R, Inta C. Molecular epidemiology and clinical features of hand, foot and mouth disease in northern Thailand in 2016: a prospective cohort study. BMC Infect Dis. 2018;18(1):630. Epub 2018/12/14. doi: 10.1186/s12879-018-3560-4 ; PubMed Central PMCID: PMC6282397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-018-3560-4</ArticleId><ArticleId IdType="pmc">PMC6282397</ArticleId><ArticleId IdType="pubmed">30522440</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirand A, Henquell C, Archimbaud C, Ughetto S, Antona D, Bailly JL, et al.. Outbreak of hand, foot and mouth disease/herpangina associated with coxsackievirus A6 and A10 infections in 2010, France: a large citywide, prospective observational study. Clin Microbiol Infect. 2012;18(5):E110–8. Epub 2012/03/13. doi: 10.1111/j.1469-0691.2012.03789.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2012.03789.x</ArticleId><ArticleId IdType="pubmed">22404077</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Dai W, Zhang C, Zhou Y, Xiong P, Wang S, et al.. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg Microbes Infect. 2018;7(1):94. Epub 2018/05/20. doi: 10.1038/s41426-018-0094-1 ; PubMed Central PMCID: PMC5959873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-018-0094-1</ArticleId><ArticleId IdType="pmc">PMC5959873</ArticleId><ArticleId IdType="pubmed">29777102</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Zhang C, Liu Q, Gong S, Geng L, Huang Z. A virus-like particle vaccine protects mice against coxsackievirus A10 lethal infection. Antiviral Res. 2018;152:124–30. Epub 2018/02/23. doi: 10.1016/j.antiviral.2018.02.016 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2018.02.016</ArticleId><ArticleId IdType="pubmed">29470994</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Dong Z, Li J, Carr MJ, Zhuang D, Wang J, et al.. Protective Efficacies of Formaldehyde-Inactivated Whole-Virus Vaccine and Antivirals in a Murine Model of Coxsackievirus A10 Infection. J Virol. 2017;91(13). Epub 2017/04/21. doi: 10.1128/JVI.00333-17 ; PubMed Central PMCID: PMC5469256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00333-17</ArticleId><ArticleId IdType="pmc">PMC5469256</ArticleId><ArticleId IdType="pubmed">28424287</ArticleId></ArticleIdList></Reference><Reference><Citation>An HH, Li M, Liu RL, Wu J, Meng SL, Guo J, et al.. Humoral and cellular immunogenicity and efficacy of a coxsackievirus A10 vaccine in mice. Emerg Microbes Infect. 2023;12(1):e2147022. Epub 2022/11/15. doi: 10.1080/22221751.2022.2147022 ; PubMed Central PMCID: PMC9848378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2147022</ArticleId><ArticleId IdType="pmc">PMC9848378</ArticleId><ArticleId IdType="pubmed">36373411</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Guo MS, Wu SR, Lin HY, Yang YT, Liu WC, et al.. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles. Antiviral Res. 2016;129:58–66. Epub 2016/02/24. doi: 10.1016/j.antiviral.2016.02.008 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.02.008</ArticleId><ArticleId IdType="pubmed">26899790</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen C, Liu Q, Zhou Y, Ku Z, Wang L, Lan K, et al.. Inactivated coxsackievirus A10 experimental vaccines protect mice against lethal viral challenge. Vaccine. 2016;34(41):5005–12. Epub 2016/08/27. doi: 10.1016/j.vaccine.2016.08.033 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.08.033</ArticleId><ArticleId IdType="pubmed">27562093</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalldorf G. The coxsackie virus group. Ann N Y Acad Sci. 1953;56(3):583–6. Epub 1953/03/31. doi: 10.1111/j.1749-6632.1953.tb30251.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1953.tb30251.x</ArticleId><ArticleId IdType="pubmed">13139263</ArticleId></ArticleIdList></Reference><Reference><Citation>Fields BN, Knipe DM, Howley PM. Fields virology. 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams &amp; Wilkins; 2007.</Citation></Reference><Reference><Citation>Zhu L, Sun Y, Fan J, Zhu B, Cao L, Gao Q, et al.. Structures of Coxsackievirus A10 unveil the molecular mechanisms of receptor binding and viral uncoating. Nat Commun. 2018;9(1):4985. Epub 2018/11/28. doi: 10.1038/s41467-018-07531-0 ; PubMed Central PMCID: PMC6255764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-07531-0</ArticleId><ArticleId IdType="pmc">PMC6255764</ArticleId><ArticleId IdType="pubmed">30478256</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu R, Xu L, Zheng Q, Cui Y, Li S, He M, et al.. Discovery and structural characterization of a therapeutic antibody against coxsackievirus A10. Sci Adv. 2018;4(9):eaat7459. Epub 2018/09/27. doi: 10.1126/sciadv.aat7459 ; PubMed Central PMCID: PMC6155056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aat7459</ArticleId><ArticleId IdType="pmc">PMC6155056</ArticleId><ArticleId IdType="pubmed">30255146</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Zhou D, Ni T, Karia D, Kotecha A, Wang X, et al.. Hand-foot-and-mouth disease virus receptor KREMEN1 binds the canyon of Coxsackie Virus A10. Nat Commun. 2020;11(1):38. Epub 2020/01/09. doi: 10.1038/s41467-019-13936-2 ; PubMed Central PMCID: PMC6946704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-13936-2</ArticleId><ArticleId IdType="pmc">PMC6946704</ArticleId><ArticleId IdType="pubmed">31911601</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Ye X, Zhang XY, Zhu Z, Zhang X, Xu Z, et al.. Coxsackievirus A10 atomic structure facilitating the discovery of a broad-spectrum inhibitor against human enteroviruses. Cell Discov. 2019;5:4. Epub 2019/01/18. doi: 10.1038/s41421-018-0073-7 ; PubMed Central PMCID: PMC6331555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-018-0073-7</ArticleId><ArticleId IdType="pmc">PMC6331555</ArticleId><ArticleId IdType="pubmed">30652025</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Y, Peng R, Song H, Tong Z, Qu X, Liu S, et al.. Molecular basis of Coxsackievirus A10 entry using the two-in-one attachment and uncoating receptor KRM1. Proc Natl Acad Sci U S A. 2020;117(31):18711–8. Epub 2020/07/22. doi: 10.1073/pnas.2005341117 ; PubMed Central PMCID: PMC7414063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2005341117</ArticleId><ArticleId IdType="pmc">PMC7414063</ArticleId><ArticleId IdType="pubmed">32690697</ArticleId></ArticleIdList></Reference><Reference><Citation>Staring J, van den Hengel LG, Raaben M, Blomen VA, Carette JE, Brummelkamp TR. KREMEN1 Is a Host Entry Receptor for a Major Group of Enteroviruses. Cell Host Microbe. 2018;23(5):636–43 e5. Epub 2018/04/24. doi: 10.1016/j.chom.2018.03.019 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2018.03.019</ArticleId><ArticleId IdType="pubmed">29681460</ArticleId></ArticleIdList></Reference><Reference><Citation>Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al.. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46(W1):W296–W303. Epub 2018/05/23. doi: 10.1093/nar/gky427 ; PubMed Central PMCID: PMC6030848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky427</ArticleId><ArticleId IdType="pmc">PMC6030848</ArticleId><ArticleId IdType="pubmed">29788355</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Liu J, Plante KS, Plante JA, Xie X, Zhang X, et al.. The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. Nature. 2022;602(7896):294–9. Epub 2021/11/25. doi: 10.1038/s41586-021-04245-0 ; PubMed Central PMCID: PMC8900207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04245-0</ArticleId><ArticleId IdType="pmc">PMC8900207</ArticleId><ArticleId IdType="pubmed">34818667</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann MG. The canyon hypothesis. Hiding the host cell receptor attachment site on a viral surface from immune surveillance. J Biol Chem. 1989;264(25):14587–90. Epub 1989/09/05. .</Citation><ArticleIdList><ArticleId IdType="pubmed">2670920</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Yan J, Zhu L, Wang M, Liu L, Yu R, et al.. The Establishment of Infectious Clone and Single Round Infectious Particles for Coxsackievirus A10. Virol Sin. 2020;35(4):426–35. Epub 2020/03/08. doi: 10.1007/s12250-020-00198-2 ; PubMed Central PMCID: PMC7462955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-020-00198-2</ArticleId><ArticleId IdType="pmc">PMC7462955</ArticleId><ArticleId IdType="pubmed">32144688</ArticleId></ArticleIdList></Reference><Reference><Citation>Lien SC, Shen YS, Lin HY, Wu SR, Fang CY, Chen CH, et al.. Propagation and immunological characterization of coxsackievirus A10 in a serum-free HEK293A cell culture system. Virus Res. 2023;329:199101. Epub 2023/03/24. doi: 10.1016/j.virusres.2023.199101 ; PubMed Central PMCID: PMC10194310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2023.199101</ArticleId><ArticleId IdType="pmc">PMC10194310</ArticleId><ArticleId IdType="pubmed">36958398</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai W, Xiong P, Zhang X, Liu Z, Chen J, Zhou Y, et al.. Recombinant virus-like particle presenting a newly identified coxsackievirus A10 neutralization epitope induces protective immunity in mice. Antiviral Res. 2019;164:139–46. Epub 2019/03/01. doi: 10.1016/j.antiviral.2019.02.016 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2019.02.016</ArticleId><ArticleId IdType="pubmed">30817941</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Xu C, Dai W, Wang Y, Liu Z, Zhang X, et al.. Functional and structural characterization of a two-MAb cocktail for delayed treatment of enterovirus D68 infections. Nat Commun. 2021;12(1):2904. Epub 2021/05/20. doi: 10.1038/s41467-021-23199-5 ; PubMed Central PMCID: PMC8131599 MAbs 2H12 and 8F12. The other authors declare no competing interests.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23199-5</ArticleId><ArticleId IdType="pmc">PMC8131599</ArticleId><ArticleId IdType="pubmed">34006855</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Liu C, Shi J, Wang Y, Xu C, Ye X, et al.. Molecular mechanism of antibody neutralization of coxsackievirus A16. Nat Commun. 2022;13(1):7854. Epub 2022/12/22. doi: 10.1038/s41467-022-35575-w ; PubMed Central PMCID: PMC9769477 the MAbs. The other authors declare that they have no competing interests.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-35575-w</ArticleId><ArticleId IdType="pmc">PMC9769477</ArticleId><ArticleId IdType="pubmed">36543790</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al.. UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–12. Epub 2004/07/21. doi: 10.1002/jcc.20084 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20084</ArticleId><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol. 2007;372(3):774–97. Epub 2007/08/08. doi: 10.1016/j.jmb.2007.05.022 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2007.05.022</ArticleId><ArticleId IdType="pubmed">17681537</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Wang Y, Zhu Y, Liu C, Gu C, Xu S, et al.. Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. Nat Commun. 2021;12(1):264. Epub 2021/01/13. doi: 10.1038/s41467-020-20465-w ; PubMed Central PMCID: PMC7801428 applications for MAbs 2H2 and 3C1. The other authors declare that they have no competing interests.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20465-w</ArticleId><ArticleId IdType="pmc">PMC7801428</ArticleId><ArticleId IdType="pubmed">33431876</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>